Andrew Huberman· PhD
so rapy historically is thought of as an immune suppressant because that's the context in which it was approved for patients — undergoing organ transplantation
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so rapy historically is thought of as an immune suppressant because that's the context in which it was approved for patients — undergoing organ transplantation
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
So, Sirolimus is approved for organ transplant rejection. As you mentioned, it's used sometimes in the setting of longevity.
Rapamycin is used to prevent organ transplant rejection and has possible anti-aging effects.
Rapomyone was first discovered in the 1960s by scientists gathering a soil sample in a cave on Easter Island In that soil sample they found a bacterium that had powerful antifungal properties They named that compound rapamy Researchers thought it might be the ultimate cure for many fungal problems such as athletes foot But before they could develop that further they also discovered rapamy was a powerful amunosuppressant In some cases amunosuppressants can save someone's life But for large portions of the population suppressing the immune system can be a death sentence In 1999 the FDA approved rapamy's usage for organ transplant patients because of its amunosuppressant properties
So it had antifungal effects, immunosuppressive effects, anti -cancer effects.
rapamycin is the name given by syren seagal to the compound identified on easter island that went through two companies before being eventually absorbed by pfizer through wyeth and that was a drug named rapamune or serolimus and that was fda approved in 1999 for transplantation
well i think it's because up until that point the only human application for rapamycin was immune suppression right that's right rapamycin is a drug i have known about forever because as a surgical resident i was giving rapamycin to kidney transplant patients heart transplant patients and liver transplant patients along with a cocktail of cyclosporine you know prednisone mmf all of these other really nasty drugs and it was one part of that in their ability to suppress the immune system
the first paper that seren seal put out there describing the chemical composition of rap ay if I'm not mistaken was about 1971 1972 the FDA approval for Ramy in humans was 1999
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.